BWVI Quote, Financials, Valuation and Earnings

Cintas Corp. has a net margin of -- compared to Psycheceutical Bioscience, Inc.'s net margin of 17.69%. Psycheceutical Bioscience, Inc.'s return on equity of -- beat Cintas Corp.'s return on equity of 41.56%.

Psycheceutical Bioscience, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Cintas Corp. has an analysts' consensus of $213.94 which suggests that it could grow by 11.93%. Given that Cintas Corp. has higher upside potential than Psycheceutical Bioscience, Inc., analysts believe Cintas Corp. is more attractive than Psycheceutical Bioscience, Inc..

Psycheceutical Bioscience, Inc. has a beta of -22.557, which suggesting that the stock is 2355.673% less volatile than S&P 500. In comparison Cintas Corp. has a beta of 0.964, suggesting its less volatile than the S&P 500 by 3.606%.

Psycheceutical Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cintas Corp. offers a yield of 0.88% to investors and pays a quarterly dividend of $0.45 per share. Psycheceutical Bioscience, Inc. pays -- of its earnings as a dividend. Cintas Corp. pays out 35.44% of its earnings as a dividend. Cintas Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Psycheceutical Bioscience, Inc. quarterly revenues are --, which are smaller than Cintas Corp. quarterly revenues of $2.8B. Psycheceutical Bioscience, Inc.'s net income of -- is lower than Cintas Corp.'s net income of $495.3M. Notably, Psycheceutical Bioscience, Inc.'s price-to-earnings ratio is -- while Cintas Corp.'s PE ratio is 41.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Psycheceutical Bioscience, Inc. is 0.01x versus 7.24x for Cintas Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Resources Connection, Inc. has a net margin of -- compared to Psycheceutical Bioscience, Inc.'s net margin of -2%. Psycheceutical Bioscience, Inc.'s return on equity of -- beat Resources Connection, Inc.'s return on equity of -66.17%.

Psycheceutical Bioscience, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Resources Connection, Inc. has an analysts' consensus of $6.88 which suggests that it could grow by 30.7%. Given that Resources Connection, Inc. has higher upside potential than Psycheceutical Bioscience, Inc., analysts believe Resources Connection, Inc. is more attractive than Psycheceutical Bioscience, Inc..

Psycheceutical Bioscience, Inc. has a beta of -22.557, which suggesting that the stock is 2355.673% less volatile than S&P 500. In comparison Resources Connection, Inc. has a beta of 0.508, suggesting its less volatile than the S&P 500 by 49.246%.

Psycheceutical Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Resources Connection, Inc. offers a yield of 6.65% to investors and pays a quarterly dividend of $0.07 per share. Psycheceutical Bioscience, Inc. pays -- of its earnings as a dividend. Resources Connection, Inc. pays out 9.72% of its earnings as a dividend. Resources Connection, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Psycheceutical Bioscience, Inc. quarterly revenues are --, which are smaller than Resources Connection, Inc. quarterly revenues of $120.2M. Psycheceutical Bioscience, Inc.'s net income of -- is lower than Resources Connection, Inc.'s net income of -$2.4M. Notably, Psycheceutical Bioscience, Inc.'s price-to-earnings ratio is -- while Resources Connection, Inc.'s PE ratio is 24.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Psycheceutical Bioscience, Inc. is 0.01x versus 0.32x for Resources Connection, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SPAR Group, Inc. has a net margin of -- compared to Psycheceutical Bioscience, Inc.'s net margin of -21.16%. Psycheceutical Bioscience, Inc.'s return on equity of -- beat SPAR Group, Inc.'s return on equity of -91.7%.

Psycheceutical Bioscience, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand SPAR Group, Inc. has an analysts' consensus of -- which suggests that it could grow by 811.46%. Given that SPAR Group, Inc. has higher upside potential than Psycheceutical Bioscience, Inc., analysts believe SPAR Group, Inc. is more attractive than Psycheceutical Bioscience, Inc..

Psycheceutical Bioscience, Inc. has a beta of -22.557, which suggesting that the stock is 2355.673% less volatile than S&P 500. In comparison SPAR Group, Inc. has a beta of 0.092, suggesting its less volatile than the S&P 500 by 90.827%.

Psycheceutical Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPAR Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Psycheceutical Bioscience, Inc. pays -- of its earnings as a dividend. SPAR Group, Inc. pays out -- of its earnings as a dividend.

Psycheceutical Bioscience, Inc. quarterly revenues are --, which are smaller than SPAR Group, Inc. quarterly revenues of $41.4M. Psycheceutical Bioscience, Inc.'s net income of -- is lower than SPAR Group, Inc.'s net income of -$8.8M. Notably, Psycheceutical Bioscience, Inc.'s price-to-earnings ratio is -- while SPAR Group, Inc.'s PE ratio is 2.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Psycheceutical Bioscience, Inc. is 0.01x versus 0.12x for SPAR Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Transcat, Inc. has a net margin of -- compared to Psycheceutical Bioscience, Inc.'s net margin of 1.54%. Psycheceutical Bioscience, Inc.'s return on equity of -- beat Transcat, Inc.'s return on equity of 3.98%.

Psycheceutical Bioscience, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Transcat, Inc. has an analysts' consensus of $103.67 which suggests that it could grow by 76.11%. Given that Transcat, Inc. has higher upside potential than Psycheceutical Bioscience, Inc., analysts believe Transcat, Inc. is more attractive than Psycheceutical Bioscience, Inc..

Psycheceutical Bioscience, Inc. has a beta of -22.557, which suggesting that the stock is 2355.673% less volatile than S&P 500. In comparison Transcat, Inc. has a beta of 0.789, suggesting its less volatile than the S&P 500 by 21.07%.

Psycheceutical Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Transcat, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Psycheceutical Bioscience, Inc. pays -- of its earnings as a dividend. Transcat, Inc. pays out -- of its earnings as a dividend.

Psycheceutical Bioscience, Inc. quarterly revenues are --, which are smaller than Transcat, Inc. quarterly revenues of $82.3M. Psycheceutical Bioscience, Inc.'s net income of -- is lower than Transcat, Inc.'s net income of $1.3M. Notably, Psycheceutical Bioscience, Inc.'s price-to-earnings ratio is -- while Transcat, Inc.'s PE ratio is 48.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Psycheceutical Bioscience, Inc. is 0.01x versus 1.82x for Transcat, Inc.. Usually stocks with elevated PS ratios are considered overvalued.